[go: up one dir, main page]

NO20081454L - Met-kinaseinhibitorer - Google Patents

Met-kinaseinhibitorer

Info

Publication number
NO20081454L
NO20081454L NO20081454A NO20081454A NO20081454L NO 20081454 L NO20081454 L NO 20081454L NO 20081454 A NO20081454 A NO 20081454A NO 20081454 A NO20081454 A NO 20081454A NO 20081454 L NO20081454 L NO 20081454L
Authority
NO
Norway
Prior art keywords
kinase inhibitors
met kinase
met
cancer
salts
Prior art date
Application number
NO20081454A
Other languages
English (en)
Inventor
David Kent Williams
John S Tokarski
Xiao Tao Chen
Robert M Borzilleri
Robert F Kaltenbach
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of NO20081454L publication Critical patent/NO20081454L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Foreliggende oppfinnelse angår forbindelser som har formel I eller II: omfattende salter derav, og metoder for anvendelse av dem for behandling av kreft.
NO20081454A 2005-09-30 2008-03-25 Met-kinaseinhibitorer NO20081454L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US72208905P 2005-09-30 2005-09-30
US11/529,875 US7547782B2 (en) 2005-09-30 2006-09-28 Met kinase inhibitors
PCT/US2006/038216 WO2007041379A1 (en) 2005-09-30 2006-09-29 Met kinase inhibitors

Publications (1)

Publication Number Publication Date
NO20081454L true NO20081454L (no) 2008-04-22

Family

ID=37547515

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20081454A NO20081454L (no) 2005-09-30 2008-03-25 Met-kinaseinhibitorer

Country Status (5)

Country Link
US (1) US7547782B2 (no)
EP (1) EP1937682B1 (no)
JP (1) JP2009510113A (no)
NO (1) NO20081454L (no)
WO (1) WO2007041379A1 (no)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2622755C (en) * 2005-10-07 2017-01-31 Exelixis, Inc. Azetidines as mek inhibitors
JP2009529047A (ja) 2006-03-07 2009-08-13 アレイ バイオファーマ、インコーポレイテッド ヘテロ二環系ピラゾール化合物およびその使用
WO2007146824A2 (en) * 2006-06-08 2007-12-21 Array Biopharma Inc. Quinoline compounds and methods of use
US7687522B2 (en) 2006-12-20 2010-03-30 Amgen Inc. Substituted pyridines and pyrimidines and their use in treatment of cancer
CA2672440A1 (en) * 2006-12-20 2008-07-03 Amgen Inc. Substituted heterocycles and methods of use
EP2121613A2 (en) 2007-01-31 2009-11-25 Vertex Pharmaceuticals, Inc. 2-aminopyridine derivatives useful as kinase inhibitors
CN101730699A (zh) * 2007-03-21 2010-06-09 百时美施贵宝公司 可用于治疗增殖性、变应性、自身免疫性和炎症性疾病的稠合杂环化合物
JP5516397B2 (ja) * 2007-04-05 2014-06-11 アムジエン・インコーポレーテツド オーロラキナーゼ調節物質及び使用方法
US8030503B2 (en) 2007-05-11 2011-10-04 Kosan Biosciences Incorporated Process for the preparation of epothilones
WO2008141234A2 (en) * 2007-05-11 2008-11-20 Kosan Biosciences Incorporated Methods of making epothilones
CN101790532B (zh) * 2007-07-31 2013-11-20 沃泰克斯药物股份有限公司 5-氟-1H-吡唑并[3，4-b]吡啶-3-胺及其衍生物的制备方法
CN101918403A (zh) * 2007-09-06 2010-12-15 阵列生物制药公司 作为酪氨酸激酶抑制剂的吡唑并吡啶类化合物
ES2389992T3 (es) 2007-11-02 2012-11-05 Vertex Pharmaceuticals Incorporated Derivados de [1H-pirazolo[3,4-b]piridin-4-il]-fenilo o -piridin-2-ilo como proteína cinasa c-theta
KR101608096B1 (ko) 2008-01-23 2016-03-31 브리스톨-마이어스 스큅 컴퍼니 ４-피리디논 화합물 및 암을 위한 그의 용도
EP2318407B1 (en) 2008-07-23 2013-01-02 Vertex Pharmaceuticals Incorporated Pyrazolopyridine kinase inhibitors
MX2011000837A (es) 2008-07-23 2011-04-05 Vertex Pharma Inhibidores de pirazolpiridina cinasa triciclica.
US8569337B2 (en) 2008-07-23 2013-10-29 Vertex Pharmaceuticals Incorporated Tri-cyclic pyrazolopyridine kinase inhibitors
US8476430B2 (en) * 2008-07-24 2013-07-02 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
AU2009279611A1 (en) * 2008-08-06 2010-02-11 Vertex Pharmaceuticals Incorporated Aminopyridine kinase inhibitors
TWI491610B (zh) * 2008-10-09 2015-07-11 必治妥美雅史谷比公司 作為激酶抑制劑之咪唑并嗒腈
EP2427464A1 (en) 2009-05-06 2012-03-14 Vertex Pharmaceuticals Incorporated Pyrazolopyridines
HRP20160967T1 (hr) 2009-10-06 2016-10-07 Millennium Pharmaceuticals, Inc. Heterociklički spojevi korisni kao pdk1 inhibitori
US9067932B2 (en) 2010-01-27 2015-06-30 Vertex Pharmaceuticals Incorporated Pyrazolopyridine kinase inhibitors
JP2013518113A (ja) 2010-01-27 2013-05-20 バーテックス ファーマシューティカルズ インコーポレイテッド ピラゾロピラジンキナーゼ阻害剤
MX2012008643A (es) 2010-01-27 2013-02-26 Vertex Pharma Inhibidores de cinasas de pirazolopiridinas.
WO2011146313A1 (en) 2010-05-19 2011-11-24 The University Of North Carolina At Chapel Hill Pyrazolopyrimidine compounds for the treatment of cancer
ES2650630T3 (es) 2011-10-03 2018-01-19 The University Of North Carolina At Chapel Hill Compuestos de pirrolopirimidina para el tratamiento del cáncer
HK1206338A1 (en) * 2012-05-22 2016-01-08 北卡罗来纳大学教堂山分校 Pyrimidine compounds for the treatment of cancer
GEP201706690B (en) 2012-10-12 2017-06-26 Exelixis Inc Novel process for making compounds for use in treatment of cancer
US9562047B2 (en) 2012-10-17 2017-02-07 The University Of North Carolina At Chapel Hill Pyrazolopyrimidine compounds for the treatment of cancer
EP2925752A4 (en) 2012-11-27 2016-06-01 Univ North Carolina PYRIMIDINE COMPOUNDS FOR CANCER TREATMENT
SI3087070T1 (en) * 2013-12-26 2018-01-31 Ignyta, Inc. Pyrazolo (1,5-a) pyridine derivatives and processes for their use
WO2015157122A1 (en) 2014-04-11 2015-10-15 The University Of North Carolina At Chapel Hill Mertk-specific pyrazolopyrimidine compounds
US10709708B2 (en) 2016-03-17 2020-07-14 The University Of North Carolina At Chapel Hill Method of treating cancer with a combination of MER tyrosine kinase inhibitor and an epidermal growth factor receptor (EGFR) inhibitor
CN116947836A (zh) 2017-04-26 2023-10-27 巴斯利尔药物国际股份公司 制备呋咱并苯并咪唑及其晶型的方法
CN110218205B (zh) * 2019-07-05 2022-04-05 辽宁大学 含吡啶结构的2,4-二芳氨基嘧啶类衍生物及其应用
TW202309022A (zh) 2021-04-13 2023-03-01 美商努法倫特公司 用於治療具egfr突變之癌症之胺基取代雜環

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3464368D1 (de) 1983-03-09 1987-07-30 Beecham Group Plc Anti-inflammatory pyrazolo pyridines
EP0151962A3 (en) 1984-01-25 1985-10-02 Beecham Group Plc Pyrazolopyridine derivatives
GB8404584D0 (en) 1984-02-22 1984-03-28 Beecham Group Plc Compounds
IE904346A1 (en) 1989-12-04 1991-06-05 Searle & Co IMIDAZO[1,2-a]PYRIDINYLALKYL COMPOUNDS FOR TREATMENT OF¹NEUROTOXIC INJURY
GB9312891D0 (en) 1993-06-22 1993-08-04 Boots Co Plc Therapeutic agents
WO1997049704A1 (en) * 1996-06-27 1997-12-31 Janssen Pharmaceutica N.V. N-[4-(heteroarylmethyl)phenyl]-heteroarylamines
CA2331735A1 (en) 1998-05-08 1999-11-18 Smithkline Beecham P.L.C. Phenylurea and phenylthio urea derivatives
AU2483400A (en) 1999-01-13 2000-08-01 Warner-Lambert Company 4'heteroaryl diarylamines
JP2000212141A (ja) * 1999-01-13 2000-08-02 Warner Lambert Co ジアリ―ルアミン
PL204437B1 (pl) 1999-05-21 2010-01-29 Bristol Myers Squibb Co Pochodna pirolotriazyny i jej zastosowanie oraz kompozycja farmaceutyczna i jej zastosowanie
WO2001057040A1 (en) 2000-02-03 2001-08-09 Abbott Laboratories 6,7-disubstituted-4-aminopyrido[2,3-d]pyrimidine compounds
EP1287001B1 (en) 2000-06-06 2004-09-29 Pfizer Products Inc. Thiophene derivatives useful as anticancer agents
SK5402003A3 (en) 2000-11-17 2004-06-08 Bristol Myers Squibb Co Methods of treating p38 kinase-associated conditions and pyrrolotriazine compounds useful as kinase inhibitors
US20020147198A1 (en) 2001-01-12 2002-10-10 Guoqing Chen Substituted arylamine derivatives and methods of use
WO2002081728A2 (en) 2001-04-06 2002-10-17 Smithkline Beecham Corporation Quinoline inhibitors of hyak1 and hyak3 kinases
AU2002345792A1 (en) 2001-06-21 2003-01-08 Pfizer Inc. Thienopyridine and thienopyrimidine anticancer agents
GB0126902D0 (en) 2001-11-08 2002-01-02 Novartis Ag Organic compounds
TW200300350A (en) 2001-11-14 2003-06-01 Bristol Myers Squibb Co C-5 modified indazolylpyrrolotriazines
US6900208B2 (en) 2002-03-28 2005-05-31 Bristol Myers Squibb Company Pyrrolopyridazine compounds and methods of use thereof for the treatment of proliferative disorders
AU2003221753A1 (en) 2002-04-23 2003-11-10 Bristol-Myers Squibb Company Aryl ketone pyrrolo-triazine compounds useful as kinase inhibitors
US6989451B2 (en) * 2002-06-04 2006-01-24 Valeant Research & Development Heterocyclic compounds and uses thereof
TWI329112B (en) * 2002-07-19 2010-08-21 Bristol Myers Squibb Co Novel inhibitors of kinases
CL2003002287A1 (es) 2002-11-25 2005-01-14 Wyeth Corp COMPUESTOS DERIVADOS DE TIENO[3,2-b]-PIRIDINA-6-CARBONITRILOS Y TIENEO[2,3-b]-PIRIDINA-5-CARBONITRILOS, COMPOSICION FARMACEUTICA, PROCEDIMIENTO DE PREPARACION Y COMPUESTOS INTERMEDIARIOS, Y SU USO EN EL TRATAMIENTO DEL CANCER, APOPLEJIA, OSTEOPOROSIS
TW200420565A (en) 2002-12-13 2004-10-16 Bristol Myers Squibb Co C-6 modified indazolylpyrrolotriazines
GB0312609D0 (en) 2003-06-02 2003-07-09 Astrazeneca Ab Novel compounds
ES2314444T3 (es) 2003-08-29 2009-03-16 Pfizer Inc. Tienopiridina-fenilacetaminasy sus derivados utiles como nuevos agentes antiangiogenicos.
WO2005044793A2 (en) 2003-10-31 2005-05-19 Takeda Pharmaceutical Company Limited Nitrogen-containing fused heterocyclic compounds

Also Published As

Publication number Publication date
EP1937682B1 (en) 2015-08-12
EP1937682A1 (en) 2008-07-02
US20070078140A1 (en) 2007-04-05
JP2009510113A (ja) 2009-03-12
US7547782B2 (en) 2009-06-16
WO2007041379A1 (en) 2007-04-12

Similar Documents

Publication Publication Date Title
NO20081454L (no) Met-kinaseinhibitorer
NO20081893L (no) 4-(3-aminopyrazol)pyrimidinderivater til anvendelse som tyrosin-kinaseinhibitorer i behandling av kreft
NO20080675L (no) P38-Map kinaseinhibitorer og metoder for deres anvendelse
NO20074634L (no) Substituerte heterocykler og deres anvendelse som CHK1-, PDK1- og PAK-inhibitorer
NO20092711L (no) Metoder for anvendelse av cyclopaminanaloger
NO20080965L (no) Cykloheksylaminisokinolonderivater som Rho-kinaseinhibotorer
NO20073859L (no) Pyrrolopyrazoler, potente kinaseinhibitorer
EA200900779A1 (ru) Производные дигидропиридина, полезные как ингибиторы протеинкиназы
NO20080150L (no) Inhibitorer av AKT-aktivitet
NO20073791L (no) Pyrazolylaminopyridinderivater anvendbare som kinaseinhibitorer
EA200901488A1 (ru) Замещенные имидазолопиридазины, как ингибиторы липидкиназы
MX2009011211A (es) Indoles sustituidos en la posicion 7 inhibidores de mci-1.
NO20065148L (no) Monocykliske heterocykler som kinase inhibitorer
EA201100580A1 (ru) Имидазопиридазинкарбонитрилы, используемые в качестве ингибиторов киназы
NO20080981L (no) Nitrocatechol-derivater som COMT-inhibitorer
NO20092569L (no) Inhibitorer av Akt-aktivitet
EA201190158A1 (ru) Производные бензофуранила для применения в качестве ингибиторов глюкокиназы
NO20083918L (no) Dihydridiazepiner anvendelige som inhibitorer av proteinkinaser
NO20083923L (no) Pyrazolkinoloner er potente parp-inhibitorer
EA201170872A1 (ru) Ингибиторы протеинкиназы
EA200970447A1 (ru) Соединения и композиции в качестве ингибиторов протеинкиназы
EA200900983A1 (ru) Соединения и композиции в качестве ингибиторов киназы
WO2007079164A3 (en) Protein kinase inhibitors
NO20083267L (no) Azaindole inhibitorer av aurora kinaser
UA94129C2 (ru) Соединения для ингибирования митоза

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application